 The eligibility criteria are patients with advanced or metastatic carcinoma of the biliary tract who are not candidates for curative surgical treatment; good performance status; no prior chemotherapy; clinical measurable tumor; good organ function and good compliance. Each cycle of chemotherapy consists of 4 weeks. On days 1, 8 and 15, gemcitabine will be given by 30-minute intravenous infusion and 5-FU and leucovorin by 24-hour continuous intravenous infusion. The dose of gemcitabine will be 1000 mgm2. The doses of 5-FU will be 2000 mgm2 and leucovorin, 300 mgm2. Treatment will continue until disease progresses or prohibitive toxicity develops. For patients with complete response CR, chemotherapy will continue for 3 additional courses after the documentation of CR. Estimated time for patient accrual is 3 years. 